Defibrotide Sodium and Olanzapine and Fluoxetine
Determining the interaction of Defibrotide Sodium and Olanzapine and Fluoxetine and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using OLANZapine together with FLUoxetine can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: It is uncertain whether olanzapine causes clinically significant prolongation of the QT interval. In pooled studies of adults as well as pooled studies of adolescents, there were no significant differences between olanzapine and placebo in the proportion of patients experiencing potentially important changes in ECG parameters, including QT, QTcF (Fridericia-corrected), and PR intervals. In clinical trials, clinically meaningful QTc prolongations (QTcF >=500 msec at any time post-baseline in patients with baseline QTcF
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.
Generic Name: defibrotide
Brand name: Defitelio
Synonyms: Defibrotide
Generic Name: fluoxetine / olanzapine
Brand name: Symbyax
Synonyms: Fluoxetine and olanzapine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Defibrotide Sodium-Olanzapine and Fluoxetine Capsules
- Defibrotide Sodium-Olanzapine Extended-Release Injection
- Defibrotide Sodium-Olanzapine injection
- Defibrotide Sodium-Olanzapine Intramuscular
- Defibrotide Sodium-Olanzapine Orally Disintegrating Tablets
- Defibrotide Sodium-Olanzapine Tablets
- Olanzapine and Fluoxetine-Definity
- Olanzapine and Fluoxetine-Defitelio
- Olanzapine and Fluoxetine-Deflazacort
- Olanzapine and Fluoxetine-Deflazacort Oral Suspension
- Olanzapine and Fluoxetine-Deflazacort Tablets
- Olanzapine and Fluoxetine-Deflux